Neesha C Dhani
Overview
Explore the profile of Neesha C Dhani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
440
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Madariaga A, Mitchell S, Pittman T, Wang L, Bowering V, Kavak N, et al.
Gynecol Oncol
. 2022 Sep;
167(2):226-233.
PMID: 36055813
Background: A double-blind, randomized, placebo-controlled, phase 2 trial assessed gemcitabine in combination with the wee1 inhibitor adavosertib or placebo in platinum resistant or refractory high grade serous ovarian cancer (HGSOC),...
12.
Siddiqui I, Bilkey J, McKee T, Serra S, Pintilie M, Do T, et al.
Front Oncol
. 2022 Aug;
12:926497.
PMID: 35978831
Background: Tumor hypoxia is theorized to contribute to the aggressive biology of pancreatic ductal adenocarcinoma (PDAC). We previously reported that hypoxia correlated with rapid tumor growth and metastasis in patient-derived...
13.
Hollebecque A, Chung H, de Miguel M, Italiano A, Machiels J, Lin C, et al.
Clin Cancer Res
. 2021 Sep;
27(23):6393-6404.
PMID: 34465599
Purpose: Immune checkpoint inhibitors show high response rates and durable clinical benefit in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) tumors. However, 50%-60% do not respond to single-agent anti-programmed death-1/programmed death ligand 1...
14.
Madariaga A, Bhat G, Wilson M, Li X, Cyriac S, Bowering V, et al.
Am J Obstet Gynecol
. 2021 Jun;
225(6):658.e1-658.e9.
PMID: 34174204
Background: Despite the growing integration of mandatory biopsies for correlative endpoints within oncology clinical trials, there are sparse data on patient-reported outcomes, perceptions, and preferences. Objective: This study aimed to...
15.
Dhani N
Clin Cancer Res
. 2021 Mar;
27(9):2372-2374.
PMID: 33653820
Nontargeted circulating tumor DNA (ctDNA) whole-genome sequencing is a novel strategy for genomic characterization of high-grade serous ovarian cancer. Changes in ctDNA levels are a sensitive indicator of disease burden...
16.
Lheureux S, Cristea M, Bruce J, Garg S, Cabanero M, Mantia-Smaldone G, et al.
Lancet
. 2021 Jan;
397(10271):281-292.
PMID: 33485453
Background: The Wee1 (WEE1hu) inhibitor adavosertib and gemcitabine have shown preclinical synergy and promising activity in early phase clinical trials. We aimed to determine the efficacy of this combination in...
17.
Madariaga A, Garg S, Bruce J, Thiryayi S, Mandilaras V, Rath P, et al.
Gynecol Oncol
. 2020 Sep;
159(2):539-545.
PMID: 32912664
Objective: We sought to evaluate the role of intrinsic chromosomal aberrations in determining favorable outcome to weekly paclitaxel (WP) in patients with epithelial ovarian cancer (EOC). Methods: We evaluated the...
18.
Lheureux S, Oaknin A, Garg S, Bruce J, Madariaga A, Dhani N, et al.
Clin Cancer Res
. 2020 May;
26(16):4206-4215.
PMID: 32444417
Purpose: PARP inhibitors (PARPi) are standard-of-care therapy for high-grade serous ovarian cancer (HGSOC). We investigated combining cediranib (antiangiogenic) with olaparib (PARPi) at emergence of PARPi resistance. Patients And Methods: The...
19.
Dhani N, Hirte H, Wang L, Burnier J, Jain A, Butler M, et al.
Clin Cancer Res
. 2020 Jan;
26(11):2477-2486.
PMID: 31992589
Purpose: The relevance of the MET/hepatocyte growth factor pathway in endometrial cancer tumor biology supports the clinical evaluation of cabozantinib in this disease. Patients And Methods: PHL86/NCI#9322 (NCT01935934) is a...
20.
Mandilaras V, Garg S, Cabanero M, Tan Q, Pastrello C, Burnier J, et al.
Int J Gynecol Cancer
. 2019 Jan;
29(2):346-352.
PMID: 30659026
Objective: Mutations in are found in the majority of high grade serous ovarian cancers, leading to gain of function or loss of function of its protein product, p53, involved in...